Furthermore, it prevented KDM4B from binding to the polo-like kinase-1 (PLK1) promoter, showing a possible mechanistic treatment approach to prostate cancer and tumors expressing high levels of KDM4B/PLK1 [143]. Here, PLK1 is linked to prostate carcinoma.